Analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to post $3.46 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from $3.00 million to $4.05 million. The firm is expected to issue its next quarterly earnings report on Wednesday, May 8th.
On average, analysts expect that Dova Pharmaceuticals will report full year sales of $29.04 million for the current financial year, with estimates ranging from $23.00 million to $33.90 million. For the next year, analysts forecast that the business will post sales of $90.02 million, with estimates ranging from $55.37 million to $120.31 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.08. The firm had revenue of $2.84 million for the quarter, compared to the consensus estimate of $3.48 million.
In other Dova Pharmaceuticals news, Director Paul B. Manning purchased 68,000 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were acquired at an average cost of $7.48 per share, with a total value of $508,640.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 60.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in Dova Pharmaceuticals by 0.8% during the third quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after buying an additional 9,312 shares in the last quarter. Nexthera Capital LP boosted its stake in shares of Dova Pharmaceuticals by 25.2% in the 3rd quarter. Nexthera Capital LP now owns 1,026,906 shares of the company’s stock valued at $21,534,000 after purchasing an additional 206,558 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Dova Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 619,604 shares of the company’s stock valued at $12,993,000 after purchasing an additional 14,985 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Dova Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock valued at $12,993,000 after purchasing an additional 14,985 shares in the last quarter. Finally, Broadfin Capital LLC acquired a new stake in shares of Dova Pharmaceuticals in the 4th quarter valued at approximately $2,667,000. Hedge funds and other institutional investors own 30.09% of the company’s stock.
Shares of DOVA traded up $0.15 during trading hours on Thursday, hitting $9.05. The company had a trading volume of 97,126 shares, compared to its average volume of 179,121. The firm has a market capitalization of $251.25 million, a PE ratio of -3.48 and a beta of 2.06. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $35.33. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.73 and a quick ratio of 5.51.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Featured Story: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.